CCL2 and kidney disorder: Our data suggest C/EBP-α exerts anti-inflammatory effects through the inhibition of MCP-1 and IL-6 expression in podocytes, which may be the basis of the observed renorotective effects of C/EBP-α against the progression of ADR-induced nephropathy in mice.